below. During the period of TH, there was essentially minimal response as 7 out of 8 pts had 0% of platelet inhibition and 1 patient had marginal response of 7%. Platelet inhibition became apparent during the re-warming phase but appeared to be relatively delayed.
TCT-738 Thrombocytes And IndividuaLization Of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention (TAILOR)
Department of Transfusion Medicine, Rigshospitalet, Copenhagen, Denmark Background: Stent thrombosis is a feared complication following stent implantation. The multi-factorial causes include low anti-platelet response (LR) to the routinely used drug, clopidogrel. Newer anti-platelet drugs such as prasugrel and ticagrelor have higher potency with less inter-individual variability in platelet response, however with an increased bleeding risk. We sought to evaluate the safety and anti-platelet effect of double-dose clopidogrel as compared with normal-dose prasugrel in patients with clopidogrel LR undergoing non-urgent PCI. Methods: ЉTAILORЉ is a randomized, open-label, single-centre trial. All patients pre-treated with clopidogrel and undergoing PCI were screened for clopidogrel LR by whole-blood aggregometry, using the Multiplate analyzer® (Dynabyte, Germany) where low response to clopidogrel was defined as Multiplate ADP Ͼ 70 units. Patients demonstrating LR were randomized to either 150 mg clopidogrel or 10 mg prasugrel (5 mg for patients Ͼ 75 years or Ͻ 60 kg). Results: Of 990 patients screened, 246 (24.9%) exhibited LR to clopidogrel. Of these, 100 (40.5%) were randomized to one of the two regimens (nϭ50 in each group); the remaining served as controls. Main reasons for non-inclusion were previous stroke, ongoing anti-coagulant treatment or inability to return for follow up visit. At 1 month, anti-platelet response was normalized in a total of 67 patients: 37 (75.5%) in the prasugrel vs 30 (61.2%) in the clopidogrel group (pϭ0.123, unadjusted). Overall, prasugrel resulted in a greater decrease in Multiplate ADP values (30.1 Ϯ21.2 U for prasugrel vs 21.2 Ϯ22.4 U for clopidogrel (pϭ0.046)). There were no bleeding episodes, myocardial infarction, stroke or death during the follow-up. Conclusions: Tailoring of anti-platelet treatment in patients with clopidogrel LR undergoing non-urgent PCI translates into improved platelet inhibition with both normaldose prasugrel and double-dose clopidogrel, however with a more pronounced effect with prasugrel.
TCT-739
Effect 
Background:
Patients with prior coronary artery bypass graft surgery (CABG) who present with an acute coronary syndrome have high risk for recurrent events. Whether more intensive antiplatelet therapy with ticagrelor might be beneficial compared to clopidogrel is unknown. In this substudy of the PLATO trial we studied the effects of randomized treatment dependent on history of CABG. Methods: Patients participating in PLATO were classified according to whether they had prior CABG. The trial's primary and secondary end points were compared using Cox proportional hazards regression. Results: Of the 18,613 study patients, 1,133 (6.5%) had prior CABG, of whom 353 (31%) underwent percutaneous coronary intervention in a saphenous vein graft and 190 (17%) in a native coronary artery. Prior CABG patients had more high risk characteristics at study entry, experienced more clinical events during follow-up, but had less major bleeding (Table) . The primary endpoint (composite of cardiovascular death, myocardial infarction, and stroke) was reduced to a similar extent by ticagrelor among patients with [19.6% vs. 21 
Conclusions:
Prior CABG patients represent a high risk cohort for death and recurrent cardiovascular events but have lower risk for major bleeding. A reduction in ischemic events without increase in major bleeding occurred with ticagrelor vs. clopidogrel in prior CABG patients, similar to the results in non-prior CABG patients.
TCT-740
Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials 
Deutsches Herzzentrum Munich, Munich, Germany
Background: There is still uncertainty regarding the optimal dual antiplatelet therapy (DAPT) duration after percutaneous coronary interventions (PCI). We evaluate benefits and risks of extending DAPT after PCI in the drug-eluting stent era. Methods: We searched electronic databases (Medline, EMBASE, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, chapters in books and proceedings of advisory panels for the US Food and Drug Administration, for randomized controlled trials investigating the clinical impact of extending DAPT duration in patients undergoing PCI. The primary endpoint was all-cause death. The secondary endpoints were myocardial infarction (MI), stent thrombosis (ST), cerebrovascular accidents (CVA) and Thrombolysis in Myocardial Infarction (TIMI) major bleeding. Results: We included four trials which randomized 8,231 patients (50.2%, extended DAPT duration versus 49.8%, control duration). A total of 8,158 patients (99.1%) were available for final analyses. Median DAPT duration was 16.8 versus 6.2 months for the extended DAPT and control groups, respectively. At follow-up (median 16. 
